MorphoSys AG (MPSYY.PK) News Headlines

▮ More

Date

Headline

2/4/2020 4:04:01 PM MorphoSys Initiates Expanded Access Program In U.S. For Tafasitamab

1/13/2020 1:54:23 AM MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S.

1/13/2020 1:38:40 AM MorphoSys Enters Global Collaboration And Licensing Agreement With Incyte

12/30/2019 8:22:20 AM MorphoSys Announces Submission Of BLA For Tafasitamab In R/r DLBCL To FDA

12/27/2019 10:54:51 PM MorphoSys:First Patient Dosed In Phase 1 Study Of Tafasitamab In Firstline DLBCL

11/11/2019 9:33:26 PM MorphoSys's Partner Presents Results For Bimagrumab In Obesity, Type 2 Diabetes

11/6/2019 4:24:46 PM MorphoSys To Present Number Of Important Updates On Tafasitamab At ASH

10/29/2019 5:56:26 PM MorphoSys Posts Q3 Loss, Reaffirms FY19 Revenue Outlook

10/29/2019 5:25:18 PM MorphoSys Says Primary Goal Of Re-MIND Study Has Been Met

10/29/2019 5:14:25 PM MorphoSys Re-affirms FY19 Guidance

10/29/2019 5:11:07 PM EARNINGS SUMMARY: Details of MorphoSys AG Q3 Earnings Report

10/29/2019 3:58:41 PM MorphoSys Says Primary Endpoint Of Re-MIND Has Been Met

10/29/2019 3:54:45 AM AZN's POSEIDON Has Poise, MRTX On The Move, MOR Drops Atopic Dermatitis Trial

10/28/2019 5:15:40 PM MorphoSys Stops Clinical Development MOR106 In Atopic Dermatitis

10/28/2019 4:55:17 PM MorphoSys: MOR106 Clinical Development In Atopic Dermatitis Ended For Futility

10/14/2019 7:22:22 AM MorphoSys And I-Mab Biopharma Announce IND Clearance To Begin Clinical Trials Of MOR202/TJ202

9/16/2019 8:18:27 AM MorphoSys's Licensee Janssen Submits Biologics License Application Of Tremfya

8/6/2019 4:44:24 PM MorphoSys Posts Narrower Loss In Q2 - Quick Facts

8/6/2019 4:19:25 PM MorphoSys Q2 Loss Per Share EUR 0.19 Vs Loss EUR 0.76 Last Year

8/6/2019 4:05:49 PM MorphoSys Report Specifications Of Biomarker Implemented In Phase 3 B-MIND Study

Morphosys Ag (MPSYY.PK)